Document Detail

Successful treatment with vincristine in PHACES syndrome.
MedLine Citation:
PMID:  17462981     Owner:  NLM     Status:  MEDLINE    
We report a case of PHACES syndrome witch was effectively treated using vincristine. A female infant was referred at 8 months of age for evaluation with a segmental mandibular haemangioma with rapid growing and facial disfigurement. The infant was initially placed on oral prednisone with clinical response but she developed obstructive sleep apnoea. Vincristine was started at about 24 months and continued for 4 months with marked decrease in the size of the haemangioma. The only side effect was constipation.
A Herrero Hernández; O Escobosa Sánchez; T Acha García
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico     Volume:  9     ISSN:  1699-048X     ISO Abbreviation:  -     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-27     Completed Date:  2007-07-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101247119     Medline TA:  Clin Transl Oncol     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  262-3     Citation Subset:  IM    
Division of Pediatric Oncology, Hospital Materno-Infantil Carlos Haya, Málaga, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Multiple*
Age Factors
Antineoplastic Agents, Hormonal / administration & dosage,  adverse effects,  therapeutic use
Antineoplastic Agents, Phytogenic / administration & dosage,  adverse effects,  therapeutic use*
Constipation / chemically induced
Eye Abnormalities*
Facial Neoplasms / congenital*,  drug therapy*
Follow-Up Studies
Glucocorticoids / administration & dosage,  adverse effects,  therapeutic use
Hemangioma / congenital*,  drug therapy*
Prednisone / administration & dosage,  adverse effects,  therapeutic use
Time Factors
Treatment Outcome
Vincristine / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Antineoplastic Agents, Phytogenic; 0/Glucocorticoids; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Breast malignant phyllodes tumour metastasising to soft tissues of oral cavity.
Next Document:  Parotid gland metastasis of a breast cancer.